Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News NervGen Pharma Corp V.NGEN

Alternate Symbol(s):  NGENF

Healthcare
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSXV:NGEN)

NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates

Newsfile November 9, 2023

Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy Kawasaki

Newsfile November 8, 2023

NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury

Newsfile October 23, 2023

NervGen Pharma Appoints John Ruffolo to Board of Directors

Newsfile October 17, 2023

NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

Newsfile September 25, 2023

NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting

Newsfile September 11, 2023

NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment Conference

Newsfile September 5, 2023

NervGen Pharma to Present on its Drug Candidate NVG-291 and Spinal Cord Injury at Investor Conference

Newsfile August 22, 2023

NervGen Pharma Reports Q2 2023 Financial Results and Operational Updates

Newsfile August 9, 2023
View More News ››

Opinion & Analysis (TSXV:NGEN)

NervGen Pharma: A “Blockbuster Drug” in the Making?

Stockhouse Editorial June 28, 2021

Alzheimer’s Breakthrough: Why the Experts are Betting on NervGen

Stockhouse Editorial April 7, 2021

Cracking the Code to Society’s Most Feared Disease

Stockhouse Editorial February 10, 2020
View More Opinion ››

Bullboard Posts (TSXV:NGEN)

NervGen Pharma: A “Blockbuster Drug” in the Making ?!

Even Biogen will be jealous
austrochris - August 9, 2023

just great news

NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and...
austrochris - August 8, 2023

RE:This has 1,000 bagger potential, article coming next week

https://finance.yahoo.com/news/nervgen-pharma-receive-more-us-123000753.html
WALLSTREEETHERO - June 28, 2023

RE:NervGen Pharma’s NVG-291-R Demonstrates Significant Function

https://finance.yahoo.com/news/nervgen-pharma-receive-more-us-123000753.html
WALLSTREEETHERO - June 28, 2023

RE:NervGen Pharma’s NVG-291-R Demonstrates Significant Function

lets go.......
WALLSTREEETHERO - June 28, 2023

Biogen Explodes Higher After Potential Mega Blockbuster Alzh

Biogen Explodes Higher After Potential Mega Blockbuster Alzheimer's Drug Succeeds (yahoo.com)
greenland - September 28, 2022
View more Bullboard ››

Prairie Provident Resources Inc

Prairie Provident Resources Inc

Prairie Provident Resources Inc. is a Canada-based oil and natural gas exploration company. The Company is engaged in the ...
View More »